© 2021 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
FDA approves immunotherapy plus targeted therapy combo for initial treatment of advanced renal cell carcinoma.
Bavencio or Keytruda plus targeted therapy slowed disease progression in Phase III studies.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
